Ascendis Pharma A/S (NASDAQ:ASND) Earns Buy Rating from Analysts at UBS Group

UBS Group assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report report published on Tuesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $196.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also recently commented on ASND. Wedbush reissued an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Stifel Nicolaus upped their target price on Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Bank of America upped their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, Wells Fargo & Company upped their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $134.43 on Tuesday. The stock has a market cap of $8.16 billion, a price-to-earnings ratio of -16.64 and a beta of 0.65. The business has a 50 day simple moving average of $132.53 and a 200 day simple moving average of $133.60. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Diversified Trust Co lifted its holdings in shares of Ascendis Pharma A/S by 7.4% during the fourth quarter. Diversified Trust Co now owns 45,038 shares of the biotechnology company’s stock valued at $6,200,000 after acquiring an additional 3,114 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the period. Exome Asset Management LLC lifted its holdings in shares of Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock valued at $6,547,000 after acquiring an additional 23,849 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at $30,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Ascendis Pharma A/S in the third quarter valued at $19,908,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.